ReviewCurrent treatment options in oncology2023
Systemic Therapy in Advanced Pleomorphic Liposarcoma: a Comprehensive Review.
Review in Current treatment options in oncology, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 10 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
10 citing papers in PubMed, 7 citations in OpenAlex.
- Liposarcoma: State of the Art-A Scoping Review.Medical sciences (Basel, Switzerland) · 2026Article
- Identification of functional genes and immune cell infiltration analysis in liposarcoma.PloS one · 2026Article
- Manganese-based nanotheranostics synergizing photothermal-chemotherapy for liposarcoma treatment.RSC advances · 2025Article
- Histomorphological and molecular characteristics of liposarcoma (Review).Oncology letters · 2025Review
- Clinical presentation, management and outcome of 11,132 patients with liposarcoma patients: a population-based study from the NETSARC+ registry.The Lancet regional health. Europe · 2025Article
- Deep Introspection Regarding Cumulative Prognostic Factors in Liposarcoma and Atypical Lipomatous Tumor.Medicina (Kaunas, Lithuania) · 2025Article
- Article
- "Enhancing Liposarcoma Prognosis - A New Predictive Scoring System Integrating Histopathological Insights".Cancer management and research · 2025Article
- MS-stable/TMB-high pleomorphic liposarcoma successfully treated with pembrolizumab: a case report.Frontiers in oncology · 2025Article
- Primary pleomorphic liposarcoma involving bilateral ovaries: Case report and literature review.Open life sciences · 2025Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
10 authors at 2 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
opinion statementThe therapeutic approach of pleomorphic liposarcoma (PLPS), a rare high-grade subgroup of soft tissue sarcoma, is commonly extrapolated from the management of other LPS subtypes. Only published retrospective data on PLPS currently serve as a guide for oncologists without clear recommendations or specific guidelines. In the advanced setting, specific systemic therapy such as eribulin and trabectedin showed promising activity in comparison to conventional therapy (doxorubicin- and gemcitabine-based protocols), which currently remains the current standard of care at initial stages of the disease. The better understanding of soft tissue sarcoma (STS) pathophysiology and disease course has led to the development of adapted clinical trial designs for rare STS histotypes with specific treatment approach.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.